Actionable Driver Events in Small Cell Lung Cancer

Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has alr...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 25; no. 1; p. 105
Main Authors Gutiérrez, Mirian, Zamora, Irene, Freeman, Michael R, Encío, Ignacio J, Rotinen, Mirja
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 20.12.2023
MDPI
Subjects
Auranofin
Cancer
Cancer therapies
Chemotherapy
Clinical trials
clinical vulnerability
Development and progression
Growth factors
Health aspects
heterogeneity
Humans
Immune system
Immunotherapy
inhibitor molecules
Kinases
Lung cancer
Lung cancer, Small cell
Lung Neoplasms - drug therapy
Medical prognosis
Metabolism
Metastasis
Morphology
Mutation
Prognosis
Proteins
Review
small cell lung cancer
Small Cell Lung Carcinoma - therapy
targeted therapy
Technology
Tobacco
Transcription factors
Tumors
targeted therapy
small cell lung cancer
inhibitor molecules
clinical vulnerability
heterogeneity
Online AccessGet full text

Cover

Abstract Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo.
AbstractList Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo.Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo.
Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo.
Audience Academic
Author Encío, Ignacio J
Freeman, Michael R
Gutiérrez, Mirian
Zamora, Irene
Rotinen, Mirja
AuthorAffiliation 4 IdiSNA, Navarre Institute for Health Research, 31006 Pamplona, Spain
2 Departments of Urology and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; michael.freeman@cshs.org
1 Department of Health Sciences, Public University of Navarre, 31008 Pamplona, Spain; mirian.gutierrez@unavarra.es (M.G.); zamora.127247@e.unavarra.es (I.Z.)
3 Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
AuthorAffiliation_xml – name: 4 IdiSNA, Navarre Institute for Health Research, 31006 Pamplona, Spain
– name: 2 Departments of Urology and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; michael.freeman@cshs.org
– name: 3 Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
– name: 1 Department of Health Sciences, Public University of Navarre, 31008 Pamplona, Spain; mirian.gutierrez@unavarra.es (M.G.); zamora.127247@e.unavarra.es (I.Z.)
Author_xml – sequence: 1
  givenname: Mirian
  orcidid: 0000-0002-2733-8904
  surname: Gutiérrez
  fullname: Gutiérrez, Mirian
  organization: Department of Health Sciences, Public University of Navarre, 31008 Pamplona, Spain
– sequence: 2
  givenname: Irene
  orcidid: 0009-0004-4723-9403
  surname: Zamora
  fullname: Zamora, Irene
  organization: Department of Health Sciences, Public University of Navarre, 31008 Pamplona, Spain
– sequence: 3
  givenname: Michael R
  surname: Freeman
  fullname: Freeman, Michael R
  organization: Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
– sequence: 4
  givenname: Ignacio J
  orcidid: 0000-0003-1732-1989
  surname: Encío
  fullname: Encío, Ignacio J
  organization: IdiSNA, Navarre Institute for Health Research, 31006 Pamplona, Spain
– sequence: 5
  givenname: Mirja
  orcidid: 0000-0002-0755-8360
  surname: Rotinen
  fullname: Rotinen, Mirja
  organization: IdiSNA, Navarre Institute for Health Research, 31006 Pamplona, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38203275$$D View this record in MEDLINE/PubMed
BookMark eNptUk2LFDEUDLLifujNszR48eCs-eykTzKMu7ow4EE9h3TyeszQnaxJ98D-e9M7s8uMyIMkvNSrUJW6RGchBkDoLcHXjDX4k98OmQpMSokX6IJwShcY1_Ls6HyOLnPeYkwZFc0rdM4UxYxKcYHo0o4-BtP2UH1JfgeputlBGHPlQ_VjMH1fraAs6ylsqpUJFtJr9LIzfYY3h_0K_bq9-bn6tlh__3q3Wq4XVmA2LqxTrXWYCcUVk9JRLo3itm6VpAKUla6zgJkyllFOgbUYE9UBASyUIjVnV-huz-ui2er75AeTHnQ0Xj82Ytpok0Zve9C8MS0I5QiVnHfQGFJ37VyOUm4aWrg-77nup3YAZ4vCZPoT0tOb4H_rTdxpgqVUkswMHw4MKf6ZII968NkWa0yAOGVNG8I4V0I1Bfr-H-g2TikUr2YULd7zR3kH1MYUBT50sTxsZ1K9lLKhpHxqXVDX_0GVcjB4W5LQ-dI_Gfi4H7Ap5pygexZJsJ4Do48DU-Dvjo15Bj8lhP0FYBe50A
Cites_doi 10.1016/j.jtho.2020.01.016
10.1183/09031936.93.01070639
10.1101/gad.328336.119
10.1158/1078-0432.CCR-11-3090
10.1158/1535-7163.MCT-21-0851
10.1200/JCO.2007.14.3461
10.1016/j.jtho.2020.09.009
10.1002/ijc.33588
10.1158/1541-7786.MCR-17-0576
10.1186/s13578-022-00862-y
10.1002/1878-0261.13124
10.1128/MCB.22.9.3129-3139.2002
10.1158/1535-7163.MCT-16-0172
10.1016/j.ccell.2016.12.005
10.1200/JCO.2018.77.7672
10.3322/caac.21660
10.21037/jtd.2020.03.89
10.1158/1078-0432.CCR-17-1606
10.1016/j.jtho.2019.08.009
10.1007/s11523-023-00965-7
10.1038/s41698-021-00218-8
10.1101/gad.338228.120
10.1158/2159-8290.CD-18-0385
10.1038/s41568-019-0133-9
10.21037/tlcr-21-437
10.1038/bjc.2017.465
10.1158/1078-0432.CCR-23-0375
10.1016/j.celrep.2023.112899
10.1016/j.ccell.2021.02.002
10.3390/cancers11101404
10.18632/oncotarget.19888
10.1038/s41572-020-00235-0
10.1002/ijc.31771
10.1016/j.jtho.2019.06.021
10.1158/1078-0432.CCR-17-2805
10.1038/ng.2396
10.21037/tlcr.2017.10.07
10.21037/tlcr.2018.01.15
10.1016/j.ccell.2021.02.014
10.1016/j.cell.2011.08.017
10.1016/j.ccell.2020.05.001
10.1073/pnas.1410419111
10.1002/1878-0261.12882
10.1016/j.jtho.2022.08.002
10.1038/celldisc.2015.26
10.1158/2159-8290.CD-17-0987
10.1016/j.jtho.2021.08.763
10.1158/1535-7163.MCT-16-0298
10.1016/j.ccell.2019.11.003
10.1038/s41467-019-13295-y
10.1126/scitranslmed.aar5012
10.1016/S1470-2045(20)30068-1
10.1158/2159-8290.CD-20-1863
10.1158/1541-7786.MCR-20-1006
10.1016/j.celrep.2022.110814
10.3390/cancers13092265
10.3390/ijms222212287
10.3390/cells9040883
10.1016/j.annonc.2021.03.207
10.1007/s12094-022-03070-9
10.1038/s41418-020-00683-x
10.3390/biomedicines9010035
10.1016/j.ccell.2018.04.001
10.21037/tlcr.2018.02.02
10.1101/gad.314815.118
10.1158/1078-0432.CCR-21-1943
10.1111/cas.15764
10.1038/s41388-022-02558-6
10.1158/1535-7163.MCT-11-0184
10.1038/s41467-023-35864-y
10.3390/ijms22116145
10.1158/1541-7786.MCR-22-0594
10.18632/oncotarget.25964
10.1111/cas.13078
10.3389/fonc.2022.1026020
10.1158/0008-5472.CAN-19-2988
10.1200/JCO.22.02823
10.1200/JCO.18.00264
10.1158/1078-0432.CCR-22-1128
10.1158/0008-5472.CAN-22-1170
10.1158/0008-5472.CAN-19-1027
10.1038/s41467-018-06162-9
10.15252/emmm.202114841
10.21037/atm-21-68
10.1158/1078-0432.CCR-18-4140
10.1126/scitranslmed.aaw7852
10.1016/j.jtho.2020.11.006
10.1158/0008-5472.CAN-16-3409
10.1056/NEJMoa1809064
10.6004/jnccn.2013.0011
10.1158/1078-0432.CCR-20-3901
10.1016/j.lungcan.2023.107216
10.1016/j.cels.2022.07.006
10.1158/1535-7163.MCT-21-0891
10.3322/caac.21785
10.1038/s43018-022-00456-0
10.1016/j.ccell.2017.01.006
10.1038/s41416-023-02185-2
10.4161/cc.10.16.17012
10.1002/ijc.20652
10.1038/nm.2473
10.1126/scisignal.aau2922
10.1038/s41416-021-01476-w
10.1158/1535-7163.MCT-19-0022
10.1093/annonc/mdi365
10.1158/0008-5472.CAN-21-3713
10.1097/JTO.0000000000000250
10.1158/1078-0432.CCR-21-0344
10.3390/ijms23042264
10.1016/j.ccell.2020.12.014
10.1158/1078-0432.CCR-22-2074
10.1097/JTO.0000000000000142
10.1016/j.cllc.2017.05.007
10.1158/1078-0432.CCR-07-2179
10.18632/oncotarget.8826
10.18632/oncotarget.27718
10.2217/imt-2021-0025
10.1002/cam4.5109
10.1016/j.celrep.2016.06.081
10.18632/oncotarget.15647
10.1016/S1470-2045(20)30539-8
10.1021/acsomega.2c03408
10.1016/S2213-2600(22)00309-5
10.1016/j.jtho.2019.01.028
10.1111/cas.13268
10.1158/1078-0432.CCR-18-0401
10.1007/s00018-013-1307-3
10.1016/j.cllc.2021.04.005
10.1016/j.jtho.2019.10.013
10.1158/2159-8290.CD-12-0112
10.1158/1078-0432.CCR-17-0443
10.15252/emmm.202217313
10.1038/s41416-021-01356-3
10.1038/nature14664
10.1016/j.jtho.2020.10.002
10.1200/PO.18.00386
10.1038/s41392-018-0008-7
10.1016/j.cell.2019.09.010
10.1007/s13577-023-00895-6
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/ijms25010105
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni Edition)
ProQuest Central
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Research Library
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Research Library
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database

CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID oai_doaj_org_article_49abe58d12744fe9a16fbfbfbd224a92
A779212506
10_3390_ijms25010105
38203275
Genre Journal Article
Review
GrantInformation_xml – fundername: Ministerio de Ciencia, Innovación y Universidades
  grantid: RYC-2018-023874-I (M.R.)
– fundername: Ministerio de Ciencia, Innovación y Universidades
  grantid: PID2019-109577RA-I00/AEI/10.13039/501100011033
– fundername: 2021/22 Predoctoral Fellowship UPNA-RYC program
  grantid: (M.G.)
– fundername: Department of Health, Government of Navarre
  grantid: 026/2022
– fundername: Spanish Ministry of Science, Innovation, and Universities
  grantid: PID2019-109577RA-I00/AEI/10.13039/501100011033
– fundername: Spanish Ministry of Science, Innovation, and Universities (Ramón y Cajal Program)
  grantid: RYC-2018-023874-I
– fundername: 2021/22 Predoctoral Fellowship UPNA-RYC program
GroupedDBID ---
29J
2WC
3V.
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
ABDBF
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ADBBV
AEAQA
AENEX
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CGR
CS3
CUY
CVF
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
ECM
EIF
EJD
ESTFP
ESX
F5P
FRP
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
ITC
KB.
KQ8
LK8
M1P
M2O
M48
M7P
MODMG
M~E
NPM
O5R
O5S
OK1
P2P
PDBOC
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNS
RPM
TR2
TUS
UKHRP
~8M
AAYXX
AFPKN
CITATION
BGLVJ
7XB
8FK
K9.
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c503t-cd8bcd035848377d247a84c6b8725e8c7dfce038ac3242e3b0018fe1e05881643
IEDL.DBID RPM
ISSN 1422-0067
1661-6596
IngestDate Fri Jul 05 11:53:41 EDT 2024
Tue Sep 17 21:28:58 EDT 2024
Wed Sep 18 16:31:47 EDT 2024
Thu Oct 10 19:51:00 EDT 2024
Fri Feb 23 00:22:27 EST 2024
Fri Feb 02 04:36:03 EST 2024
Fri Aug 23 00:56:31 EDT 2024
Sun Oct 13 10:27:21 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords targeted therapy
small cell lung cancer
inhibitor molecules
clinical vulnerability
heterogeneity
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c503t-cd8bcd035848377d247a84c6b8725e8c7dfce038ac3242e3b0018fe1e05881643
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0009-0004-4723-9403
0000-0002-2733-8904
0000-0003-1732-1989
0000-0002-0755-8360
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778712/
PMID 38203275
PQID 2912820464
PQPubID 2032341
ParticipantIDs doaj_primary_oai_doaj_org_article_49abe58d12744fe9a16fbfbfbd224a92
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10778712
proquest_miscellaneous_2913448589
proquest_journals_2912820464
gale_infotracmisc_A779212506
gale_infotracacademiconefile_A779212506
crossref_primary_10_3390_ijms25010105
pubmed_primary_38203275
PublicationCentury 2000
PublicationDate 20231220
PublicationDateYYYYMMDD 2023-12-20
PublicationDate_xml – month: 12
  year: 2023
  text: 20231220
  day: 20
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Poirier (ref_31) 2020; 15
ref_136
Zhang (ref_74) 2021; 125
Byers (ref_132) 2017; 8
Beaulieu (ref_49) 2019; 11
Suzuki (ref_60) 2021; 81
Goldman (ref_11) 2021; 22
Yotsumoto (ref_118) 2020; 11
ref_134
Kalemkerian (ref_7) 2013; 11
Kim (ref_14) 2018; 7
Taniguchi (ref_97) 2022; 39
Kodama (ref_103) 2023; 42
Thomas (ref_79) 2021; 39
Fan (ref_144) 2021; 16
Cristea (ref_105) 2020; 80
ref_128
ref_127
Augustyn (ref_20) 2014; 111
Sriuranpong (ref_29) 2002; 22
Voigt (ref_18) 2021; 19
ref_24
Huang (ref_35) 2018; 32
Byers (ref_70) 2012; 2
Ploumaki (ref_113) 2023; 25
Kornstein (ref_109) 1994; 145
ref_121
Costanzo (ref_67) 2022; 14
Hiatt (ref_44) 2022; 28
Chen (ref_52) 2018; 3
Kim (ref_126) 2022; 82
Taniguchi (ref_131) 2017; 108
Gautschi (ref_83) 2008; 14
Laird (ref_78) 2018; 24
Megyesfalvi (ref_59) 2023; 73
Scarpa (ref_25) 1988; 1
Trigo (ref_69) 2020; 21
Sekido (ref_135) 1991; 51
Lehman (ref_115) 2019; 144
Groves (ref_38) 2022; 13
Chu (ref_122) 2022; 3
Borromeo (ref_27) 2016; 16
Shue (ref_36) 2018; 7
Rudin (ref_3) 2021; 7
Peng (ref_100) 2022; 7
George (ref_12) 2015; 524
Yan (ref_42) 2022; 16
Dingemans (ref_6) 2021; 32
Umemura (ref_16) 2014; 9
Johnson (ref_138) 2003; 9
Offin (ref_23) 2019; 3
Kundu (ref_75) 2021; 10
Ramkumar (ref_114) 2023; 29
Sung (ref_1) 2021; 71
Hellmann (ref_9) 2018; 33
Gay (ref_41) 2021; 39
Horn (ref_10) 2018; 379
Owonikoko (ref_72) 2019; 37
Tang (ref_76) 2018; 24
Hsu (ref_90) 2019; 14
Zhang (ref_26) 2018; 7
Murai (ref_47) 2015; 1
Jia (ref_58) 2018; 8
Dy (ref_139) 2005; 16
Yang (ref_21) 2018; 8
Fiorentino (ref_50) 2016; 7
Kim (ref_13) 2019; 51
Zhao (ref_91) 2021; 15
Delmore (ref_53) 2011; 146
Jones (ref_93) 2023; 29
Redin (ref_101) 2022; 17
ref_51
Bauer (ref_95) 2023; 18
Ferone (ref_22) 2020; 34
Xia (ref_57) 2018; 16
Li (ref_104) 2019; 11
Hook (ref_84) 2012; 11
Peifer (ref_15) 2012; 44
Baine (ref_28) 2020; 15
Horie (ref_33) 2023; 114
Champiat (ref_124) 2023; 41
Gao (ref_140) 2023; 14
Qu (ref_30) 2022; 17
Horie (ref_37) 2016; 107
Cheng (ref_142) 2021; 125
Majeed (ref_141) 2022; 28
Song (ref_145) 2021; 13
Shia (ref_63) 2023; 42
Glisson (ref_133) 2017; 18
Gardner (ref_48) 2017; 31
Nishiga (ref_117) 2022; 3
Ouadah (ref_39) 2019; 179
Whalen (ref_116) 2019; 18
Oser (ref_46) 2019; 33
Lim (ref_8) 2021; 9
ref_62
Nomura (ref_102) 2018; 9
Wiedemeyer (ref_119) 2022; 21
Sun (ref_143) 2018; 118
Augert (ref_43) 2019; 12
Sen (ref_94) 2019; 14
Enfield (ref_61) 2019; 10
Sen (ref_55) 2017; 77
Inamura (ref_82) 2017; 8
Byers (ref_92) 2021; 22
Chalishazar (ref_107) 2019; 25
Pietanza (ref_73) 2018; 36
Krebs (ref_77) 2023; 180
Frese (ref_40) 2021; 39
Stefani (ref_88) 2022; 12
Kelenis (ref_120) 2022; 82
Rudin (ref_111) 2012; 18
Rudin (ref_32) 2019; 19
Pandiella (ref_106) 2021; 5
Ireland (ref_17) 2020; 38
Owonikoko (ref_34) 2021; 16
Wagner (ref_125) 2018; 9
Varghese (ref_4) 2014; 9
Owonikoko (ref_87) 2020; 15
Jin (ref_129) 2022; 28
Park (ref_19) 2011; 10
Bauer (ref_45) 2019; 14
Helfrich (ref_85) 2016; 15
Johnson (ref_86) 2023; 128
Taniguchi (ref_130) 2021; 11
Lallo (ref_96) 2018; 24
Ferlay (ref_2) 2021; 149
Zhang (ref_98) 2020; 37
Lochmann (ref_110) 2018; 24
Mollaoglu (ref_54) 2017; 31
Chen (ref_56) 2023; 21
Robles (ref_66) 2016; 15
Li (ref_80) 2023; 12
Decaudin (ref_137) 2005; 113
Mito (ref_64) 2023; 36
Singh (ref_68) 2021; 27
Sun (ref_99) 2022; 21
Lucantoni (ref_108) 2021; 28
Schultz (ref_81) 2023; 15
Aix (ref_65) 2023; 11
Barayan (ref_71) 2020; 12
ref_5
Park (ref_123) 2011; 17
Patil (ref_89) 2013; 70
Rudin (ref_112) 2008; 26
References_xml – volume: 15
  start-page: 520
  year: 2020
  ident: ref_31
  article-title: New Approaches to SCLC Therapy: From the Laboratory to the Clinic
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2020.01.016
  contributor:
    fullname: Poirier
– volume: 1
  start-page: 639
  year: 1988
  ident: ref_25
  article-title: Small Cell Lung Cancer Cell Lines: Pure and Variant Types Can Be Distinguished by Their Extracellular Matrix Synthesis
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.93.01070639
  contributor:
    fullname: Scarpa
– volume: 33
  start-page: 1718
  year: 2019
  ident: ref_46
  article-title: The KDM5A/RBP2 Histone Demethylase Represses NOTCH Signaling to Sustain Neuroendocrine Differentiation and Promote Small Cell Lung Cancer Tumorigenesis
  publication-title: Genes Dev.
  doi: 10.1101/gad.328336.119
  contributor:
    fullname: Oser
– volume: 18
  start-page: 3163
  year: 2012
  ident: ref_111
  article-title: Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-3090
  contributor:
    fullname: Rudin
– volume: 21
  start-page: 986
  year: 2022
  ident: ref_119
  article-title: ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-21-0851
  contributor:
    fullname: Wiedemeyer
– volume: 26
  start-page: 870
  year: 2008
  ident: ref_112
  article-title: Randomized Phase II Study of Carboplatin and Etoposide with or without the Bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2007.14.3461
  contributor:
    fullname: Rudin
– volume: 15
  start-page: 1823
  year: 2020
  ident: ref_28
  article-title: SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2020.09.009
  contributor:
    fullname: Baine
– volume: 149
  start-page: 778
  year: 2021
  ident: ref_2
  article-title: Cancer Statistics for the Year 2020: An Overview
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.33588
  contributor:
    fullname: Ferlay
– volume: 16
  start-page: 825
  year: 2018
  ident: ref_57
  article-title: Targeting CREB Pathway Suppresses Small Cell Lung Cancer
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-17-0576
  contributor:
    fullname: Xia
– ident: ref_128
  doi: 10.1186/s13578-022-00862-y
– volume: 16
  start-page: 1309
  year: 2022
  ident: ref_42
  article-title: Intrinsic and Acquired Drug Resistance to LSD1 Inhibitors in Small Cell Lung Cancer Occurs through a TEAD4-driven Transcriptional State
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.13124
  contributor:
    fullname: Yan
– volume: 22
  start-page: 3129
  year: 2002
  ident: ref_29
  article-title: Notch Signaling Induces Rapid Degradation of Achaete-Scute Homolog 1
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.22.9.3129-3139.2002
  contributor:
    fullname: Sriuranpong
– volume: 15
  start-page: 2399
  year: 2016
  ident: ref_66
  article-title: Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-16-0172
  contributor:
    fullname: Robles
– volume: 31
  start-page: 270
  year: 2017
  ident: ref_54
  article-title: MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.12.005
  contributor:
    fullname: Mollaoglu
– volume: 36
  start-page: 2386
  year: 2018
  ident: ref_73
  article-title: Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2018.77.7672
  contributor:
    fullname: Pietanza
– volume: 71
  start-page: 209
  year: 2021
  ident: ref_1
  article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
  contributor:
    fullname: Sung
– volume: 12
  start-page: 6240
  year: 2020
  ident: ref_71
  article-title: PARP Inhibitors for Small Cell Lung Cancer and Their Potential for Integration into Current Treatment Approaches
  publication-title: J. Thorac. Dis.
  doi: 10.21037/jtd.2020.03.89
  contributor:
    fullname: Barayan
– volume: 24
  start-page: 360
  year: 2018
  ident: ref_110
  article-title: Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-1606
  contributor:
    fullname: Lochmann
– volume: 14
  start-page: 2152
  year: 2019
  ident: ref_94
  article-title: Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.08.009
  contributor:
    fullname: Sen
– volume: 3
  start-page: 100400
  year: 2022
  ident: ref_122
  article-title: BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
  publication-title: JTO Clin. Res. Rep.
  contributor:
    fullname: Chu
– volume: 18
  start-page: 517
  year: 2023
  ident: ref_95
  article-title: A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
  publication-title: Target. Oncol.
  doi: 10.1007/s11523-023-00965-7
  contributor:
    fullname: Bauer
– volume: 5
  start-page: 78
  year: 2021
  ident: ref_106
  article-title: Clinical, Genetic and Pharmacological Data Support Targeting the MEK5/ERK5 Module in Lung Cancer
  publication-title: NPJ Precis. Oncol.
  doi: 10.1038/s41698-021-00218-8
  contributor:
    fullname: Pandiella
– volume: 34
  start-page: 1017
  year: 2020
  ident: ref_22
  article-title: Cells of Origin of Lung Cancers: Lessons from Mouse Studies
  publication-title: Genes Dev.
  doi: 10.1101/gad.338228.120
  contributor:
    fullname: Ferone
– volume: 8
  start-page: 1422
  year: 2018
  ident: ref_58
  article-title: Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0385
  contributor:
    fullname: Jia
– volume: 19
  start-page: 289
  year: 2019
  ident: ref_32
  article-title: Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0133-9
  contributor:
    fullname: Rudin
– volume: 10
  start-page: 4095
  year: 2021
  ident: ref_75
  article-title: SLFN11 Biomarker Status Predicts Response to Lurbinectedin as a Single Agent and in Combination with ATR Inhibition in Small Cell Lung Cancer
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr-21-437
  contributor:
    fullname: Kundu
– volume: 118
  start-page: 648
  year: 2018
  ident: ref_143
  article-title: Pazopanib Maintenance after First-Line Etoposide and Platinum Chemotherapy in Patients with Extensive Disease Small-Cell Lung Cancer: A Multicentre, Randomised, Placebo-Controlled Phase II Study (KCSG-LU12-07)
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2017.465
  contributor:
    fullname: Sun
– volume: 29
  start-page: 3237
  year: 2023
  ident: ref_114
  article-title: Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-23-0375
  contributor:
    fullname: Ramkumar
– volume: 9
  start-page: 5880
  year: 2003
  ident: ref_138
  article-title: Phase II Study of Imatinib in Patients with Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Johnson
– volume: 42
  start-page: 112899
  year: 2023
  ident: ref_103
  article-title: Modulation of Host Glutamine Anabolism Enhances the Sensitivity of Small Cell Lung Cancer to Chemotherapy
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2023.112899
  contributor:
    fullname: Kodama
– volume: 39
  start-page: 297
  year: 2021
  ident: ref_40
  article-title: Small Cell Lung Cancer Enters the Era of Precision Medicine
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.02.002
  contributor:
    fullname: Frese
– ident: ref_134
  doi: 10.3390/cancers11101404
– volume: 8
  start-page: 81441
  year: 2017
  ident: ref_132
  article-title: A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination with Platinum Etoposide Chemotherapy in Platinum-Refractory Small Cell Lung Cancer Patients
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19888
  contributor:
    fullname: Byers
– volume: 7
  start-page: 3
  year: 2021
  ident: ref_3
  article-title: Small-Cell Lung Cancer
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/s41572-020-00235-0
  contributor:
    fullname: Rudin
– volume: 144
  start-page: 1104
  year: 2019
  ident: ref_115
  article-title: Somatostatin Receptor 2 Signaling Promotes Growth and Tumor Survival in Small-cell Lung Cancer
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.31771
  contributor:
    fullname: Lehman
– volume: 14
  start-page: 1828
  year: 2019
  ident: ref_45
  article-title: Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.06.021
  contributor:
    fullname: Bauer
– volume: 24
  start-page: 5153
  year: 2018
  ident: ref_96
  article-title: The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-2805
  contributor:
    fullname: Lallo
– volume: 44
  start-page: 1104
  year: 2012
  ident: ref_15
  article-title: Integrative Genome Analyses Identify Key Somatic Driver Mutations of Small-Cell Lung Cancer
  publication-title: Nat. Genet.
  doi: 10.1038/ng.2396
  contributor:
    fullname: Peifer
– volume: 51
  start-page: 2416
  year: 1991
  ident: ref_135
  article-title: Preferential Expression of C-Kit Protooncogene Transcripts in Small Cell Lung Cancer
  publication-title: Cancer Res.
  contributor:
    fullname: Sekido
– volume: 7
  start-page: 4
  year: 2018
  ident: ref_14
  article-title: Transcriptional Deregulation Underlying the Pathogenesis of Small Cell Lung Cancer
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr.2017.10.07
  contributor:
    fullname: Kim
– volume: 7
  start-page: 21
  year: 2018
  ident: ref_36
  article-title: Tumor Heterogeneity in Small Cell Lung Cancer Defined and Investigated in Pre-Clinical Mouse Models
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr.2018.01.15
  contributor:
    fullname: Shue
– volume: 39
  start-page: 566
  year: 2021
  ident: ref_79
  article-title: Therapeutic Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.02.014
  contributor:
    fullname: Thomas
– volume: 146
  start-page: 904
  year: 2011
  ident: ref_53
  article-title: BET Bromodomain Inhibition as a Therapeutic Strategy to Target C-Myc
  publication-title: Cell
  doi: 10.1016/j.cell.2011.08.017
  contributor:
    fullname: Delmore
– volume: 38
  start-page: 60
  year: 2020
  ident: ref_17
  article-title: MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.05.001
  contributor:
    fullname: Ireland
– volume: 111
  start-page: 14788
  year: 2014
  ident: ref_20
  article-title: ASCL1 Is a Lineage Oncogene Providing Therapeutic Targets for High-Grade Neuroendocrine Lung Cancers
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1410419111
  contributor:
    fullname: Augustyn
– volume: 15
  start-page: 1130
  year: 2021
  ident: ref_91
  article-title: Acquired Small Cell Lung Cancer Resistance to Chk1 Inhibitors Involves Wee1 Up-regulation
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12882
  contributor:
    fullname: Zhao
– volume: 17
  start-page: 1387
  year: 2022
  ident: ref_101
  article-title: YES1 Is a Druggable Oncogenic Target in SCLC
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2022.08.002
  contributor:
    fullname: Redin
– volume: 1
  start-page: 15026
  year: 2015
  ident: ref_47
  article-title: EZH2 Promotes Progression of Small Cell Lung Cancer by Suppressing the TGF-β-Smad-ASCL1 Pathway
  publication-title: Cell Discov.
  doi: 10.1038/celldisc.2015.26
  contributor:
    fullname: Murai
– volume: 8
  start-page: 1316
  year: 2018
  ident: ref_21
  article-title: Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-17-0987
  contributor:
    fullname: Yang
– volume: 17
  start-page: 141
  year: 2022
  ident: ref_30
  article-title: Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2021.08.763
  contributor:
    fullname: Qu
– volume: 15
  start-page: 2314
  year: 2016
  ident: ref_85
  article-title: Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-16-0298
  contributor:
    fullname: Helfrich
– volume: 37
  start-page: 37
  year: 2020
  ident: ref_98
  article-title: CDK7 Inhibition Potentiates Genome Instability Triggering Anti-Tumor Immunity in Small Cell Lung Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.11.003
  contributor:
    fullname: Zhang
– volume: 10
  start-page: 5438
  year: 2019
  ident: ref_61
  article-title: Epithelial Tumor Suppressor ELF3 Is a Lineage-Specific Amplified Oncogene in Lung Adenocarcinoma
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-13295-y
  contributor:
    fullname: Enfield
– volume: 11
  start-page: eaar5012
  year: 2019
  ident: ref_49
  article-title: Intrinsic Cell-Penetrating Activity Propels Omomyc from Proof of Concept to Viable Anti-MYC Therapy
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aar5012
  contributor:
    fullname: Beaulieu
– volume: 21
  start-page: 645
  year: 2020
  ident: ref_69
  article-title: Lurbinectedin as Second-Line Treatment for Patients with Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30068-1
  contributor:
    fullname: Trigo
– volume: 11
  start-page: 3028
  year: 2021
  ident: ref_130
  article-title: Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-1863
  contributor:
    fullname: Taniguchi
– volume: 19
  start-page: 2015
  year: 2021
  ident: ref_18
  article-title: Sox2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-20-1006
  contributor:
    fullname: Voigt
– volume: 39
  start-page: 110814
  year: 2022
  ident: ref_97
  article-title: WEE1 Inhibition Enhances the Antitumor Immune Response to PD-L1 Blockade by the Concomitant Activation of STING and STAT1 Pathways in SCLC
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2022.110814
  contributor:
    fullname: Taniguchi
– ident: ref_24
  doi: 10.3390/cancers13092265
– ident: ref_62
  doi: 10.3390/ijms222212287
– ident: ref_51
  doi: 10.3390/cells9040883
– volume: 32
  start-page: 839
  year: 2021
  ident: ref_6
  article-title: Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.03.207
  contributor:
    fullname: Dingemans
– volume: 25
  start-page: 1554
  year: 2023
  ident: ref_113
  article-title: Bcl-2 Pathway Inhibition in Solid Tumors: A Review of Clinical Trials
  publication-title: Clin. Transl. Oncol.
  doi: 10.1007/s12094-022-03070-9
  contributor:
    fullname: Ploumaki
– volume: 28
  start-page: 1512
  year: 2021
  ident: ref_108
  article-title: BCL(X)L and BCL2 Increase the Metabolic Fitness of Breast Cancer Cells: A Single-Cell Imaging Study
  publication-title: Cell Death Differ.
  doi: 10.1038/s41418-020-00683-x
  contributor:
    fullname: Lucantoni
– ident: ref_127
  doi: 10.3390/biomedicines9010035
– volume: 33
  start-page: 853
  year: 2018
  ident: ref_9
  article-title: Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.04.001
  contributor:
    fullname: Hellmann
– volume: 7
  start-page: 32
  year: 2018
  ident: ref_26
  article-title: Small Cell Lung Cancer Tumors and Preclinical Models Display Heterogeneity of Neuroendocrine Phenotypes
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr.2018.02.02
  contributor:
    fullname: Zhang
– volume: 32
  start-page: 915
  year: 2018
  ident: ref_35
  article-title: POU2F3 Is a Master Regulator of a Tuft Cell-like Variant of Small Cell Lung Cancer
  publication-title: Genes Dev.
  doi: 10.1101/gad.314815.118
  contributor:
    fullname: Huang
– volume: 28
  start-page: 526
  year: 2022
  ident: ref_129
  article-title: Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-1943
  contributor:
    fullname: Jin
– volume: 114
  start-page: 2596
  year: 2023
  ident: ref_33
  article-title: An Integrative Epigenomic Approach Identifies ELF3 as an Oncogenic Regulator in ASCL1 -positive Neuroendocrine Carcinoma
  publication-title: Cancer Sci.
  doi: 10.1111/cas.15764
  contributor:
    fullname: Horie
– volume: 42
  start-page: 434
  year: 2023
  ident: ref_63
  article-title: Targeting PEA3 Transcription Factors to Mitigate Small Cell Lung Cancer Progression
  publication-title: Oncogene
  doi: 10.1038/s41388-022-02558-6
  contributor:
    fullname: Shia
– volume: 11
  start-page: 710
  year: 2012
  ident: ref_84
  article-title: An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-11-0184
  contributor:
    fullname: Hook
– volume: 14
  start-page: 363
  year: 2023
  ident: ref_140
  article-title: The NFIB/CARM1 Partnership Is a Driver in Preclinical Models of Small Cell Lung Cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-023-35864-y
  contributor:
    fullname: Gao
– ident: ref_121
  doi: 10.3390/ijms22116145
– volume: 21
  start-page: 91
  year: 2023
  ident: ref_56
  article-title: BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-22-0594
  contributor:
    fullname: Chen
– volume: 9
  start-page: 32278
  year: 2018
  ident: ref_102
  article-title: A Metabolic Vulnerability of Small-Cell Lung Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25964
  contributor:
    fullname: Nomura
– volume: 107
  start-page: 1755
  year: 2016
  ident: ref_37
  article-title: YAP and TAZ Modulate Cell Phenotype in a Subset of Small Cell Lung Cancer
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13078
  contributor:
    fullname: Horie
– volume: 12
  start-page: 1026020
  year: 2022
  ident: ref_88
  article-title: Unweaving the Mitotic Spindle: A Focus on Aurora Kinase Inhibitors in Lung Cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.1026020
  contributor:
    fullname: Stefani
– volume: 81
  start-page: 489
  year: 2021
  ident: ref_60
  article-title: E74-like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-2988
  contributor:
    fullname: Suzuki
– volume: 41
  start-page: 2893
  year: 2023
  ident: ref_124
  article-title: Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.22.02823
  contributor:
    fullname: Champiat
– volume: 37
  start-page: 222
  year: 2019
  ident: ref_72
  article-title: Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.00264
  contributor:
    fullname: Owonikoko
– ident: ref_5
– volume: 28
  start-page: 4551
  year: 2022
  ident: ref_44
  article-title: Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-22-1128
  contributor:
    fullname: Hiatt
– volume: 82
  start-page: 4219
  year: 2022
  ident: ref_126
  article-title: WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-22-1170
  contributor:
    fullname: Kim
– volume: 80
  start-page: 1293
  year: 2020
  ident: ref_105
  article-title: The MEK5–ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-1027
  contributor:
    fullname: Cristea
– volume: 9
  start-page: 3787
  year: 2018
  ident: ref_125
  article-title: Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-06162-9
  contributor:
    fullname: Wagner
– volume: 14
  start-page: e14841
  year: 2022
  ident: ref_67
  article-title: Promoters of ASCL1- and NEUROD1-dependent Genes Are Specific Targets of Lurbinectedin in SCLC Cells
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.202114841
  contributor:
    fullname: Costanzo
– volume: 9
  start-page: 809
  year: 2021
  ident: ref_8
  article-title: A Narrative Review of Current and Potential Prognostic Biomarkers for Immunotherapy in Small-Cell Lung Cancer
  publication-title: Ann. Transl. Med.
  doi: 10.21037/atm-21-68
  contributor:
    fullname: Lim
– volume: 25
  start-page: 5107
  year: 2019
  ident: ref_107
  article-title: MYC-Driven Small-Cell Lung Cancer Is Metabolically Distinct and Vulnerable to Arginine Depletion
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-4140
  contributor:
    fullname: Chalishazar
– volume: 11
  start-page: eaaw7852
  year: 2019
  ident: ref_104
  article-title: Identification of DHODH as a Therapeutic Target in Small Cell Lung Cancer
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aaw7852
  contributor:
    fullname: Li
– volume: 16
  start-page: 464
  year: 2021
  ident: ref_34
  article-title: YAP1 Expression in SCLC Defines a Distinct Subtype With T-Cell–Inflamed Phenotype
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2020.11.006
  contributor:
    fullname: Owonikoko
– volume: 77
  start-page: 3870
  year: 2017
  ident: ref_55
  article-title: CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3409
  contributor:
    fullname: Sen
– volume: 379
  start-page: 2220
  year: 2018
  ident: ref_10
  article-title: First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809064
  contributor:
    fullname: Horn
– volume: 11
  start-page: 78
  year: 2013
  ident: ref_7
  article-title: Small Cell Lung Cancer
  publication-title: J. Natl. Compr. Cancer Netw.
  doi: 10.6004/jnccn.2013.0011
  contributor:
    fullname: Kalemkerian
– volume: 27
  start-page: 2378
  year: 2021
  ident: ref_68
  article-title: FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-3901
  contributor:
    fullname: Singh
– volume: 180
  start-page: 107216
  year: 2023
  ident: ref_77
  article-title: Olaparib and Durvalumab in Patients with Relapsed Small Cell Lung Cancer (MEDIOLA): An Open-Label, Multicenter, Phase 1/2, Basket Study
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2023.107216
  contributor:
    fullname: Krebs
– volume: 13
  start-page: 690
  year: 2022
  ident: ref_38
  article-title: Archetype Tasks Link Intratumoral Heterogeneity to Plasticity and Cancer Hallmarks in Small Cell Lung Cancer
  publication-title: Cell Systems
  doi: 10.1016/j.cels.2022.07.006
  contributor:
    fullname: Groves
– volume: 21
  start-page: 1430
  year: 2022
  ident: ref_99
  article-title: CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-21-0891
  contributor:
    fullname: Sun
– volume: 73
  start-page: 620
  year: 2023
  ident: ref_59
  article-title: Clinical Insights into Small Cell Lung Cancer: Tumor Heterogeneity, Diagnosis, Therapy, and Future Directions
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21785
  contributor:
    fullname: Megyesfalvi
– volume: 3
  start-page: 1351
  year: 2022
  ident: ref_117
  article-title: Radiotherapy in Combination with CD47 Blockade Elicits a Macrophage-Mediated Abscopal Effect
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-022-00456-0
  contributor:
    fullname: Nishiga
– volume: 31
  start-page: 286
  year: 2017
  ident: ref_48
  article-title: Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.01.006
  contributor:
    fullname: Gardner
– volume: 128
  start-page: 1906
  year: 2023
  ident: ref_86
  article-title: Safety, Tolerability, and Pharmacokinetics of Aurora Kinase B Inhibitor AZD2811: A Phase 1 Dose-Finding Study in Patients with Advanced Solid Tumours
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-023-02185-2
  contributor:
    fullname: Johnson
– volume: 10
  start-page: 2806
  year: 2011
  ident: ref_19
  article-title: Characterization of the Cell of Origin for Small Cell Lung Cancer
  publication-title: Cell Cycle
  doi: 10.4161/cc.10.16.17012
  contributor:
    fullname: Park
– volume: 113
  start-page: 849
  year: 2005
  ident: ref_137
  article-title: In Vivo Efficacy of STI571 in Xenografted Human Small Cell Lung Cancer Alone or Combined with Chemotherapy
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.20652
  contributor:
    fullname: Decaudin
– volume: 17
  start-page: 1504
  year: 2011
  ident: ref_123
  article-title: A Crucial Requirement for Hedgehog Signaling in Small Cell Lung Cancer
  publication-title: Nat. Med.
  doi: 10.1038/nm.2473
  contributor:
    fullname: Park
– volume: 12
  start-page: eaau2922
  year: 2019
  ident: ref_43
  article-title: Targeting NOTCH Activation in Small Cell Lung Cancer through LSD1 Inhibition
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.aau2922
  contributor:
    fullname: Augert
– volume: 125
  start-page: 1333
  year: 2021
  ident: ref_74
  article-title: A Wake-up Call for Cancer DNA Damage: The Role of Schlafen 11 (SLFN11) across Multiple Cancers
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-021-01476-w
  contributor:
    fullname: Zhang
– volume: 18
  start-page: 1926
  year: 2019
  ident: ref_116
  article-title: Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-19-0022
  contributor:
    fullname: Whalen
– volume: 16
  start-page: 1811
  year: 2005
  ident: ref_139
  article-title: A Phase II Trial of Imatinib (ST1571) in Patients with c-Kit Expressing Relapsed Small-Cell Lung Cancer: A CALGB and NCCTG Study
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdi365
  contributor:
    fullname: Dy
– volume: 82
  start-page: 3058
  year: 2022
  ident: ref_120
  article-title: Inhibition of Karyopherin Β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-21-3713
  contributor:
    fullname: Kelenis
– volume: 9
  start-page: 1324
  year: 2014
  ident: ref_16
  article-title: Therapeutic Priority of the PI3K/AKT/MTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0000000000000250
  contributor:
    fullname: Umemura
– volume: 28
  start-page: 1966
  year: 2022
  ident: ref_141
  article-title: Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 Is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-0344
  contributor:
    fullname: Majeed
– volume: 51
  start-page: 1
  year: 2019
  ident: ref_13
  article-title: Recent Progress in Mapping the Emerging Landscape of the Small-Cell Lung Cancer Genome
  publication-title: Exp. Mol. Med.
  contributor:
    fullname: Kim
– ident: ref_136
  doi: 10.3390/ijms23042264
– volume: 39
  start-page: 346
  year: 2021
  ident: ref_41
  article-title: Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.12.014
  contributor:
    fullname: Gay
– volume: 29
  start-page: 331
  year: 2023
  ident: ref_93
  article-title: A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-22-2074
  contributor:
    fullname: Jones
– volume: 9
  start-page: 892
  year: 2014
  ident: ref_4
  article-title: Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0000000000000142
  contributor:
    fullname: Varghese
– volume: 18
  start-page: 615
  year: 2017
  ident: ref_133
  article-title: A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2017.05.007
  contributor:
    fullname: Glisson
– volume: 14
  start-page: 1639
  year: 2008
  ident: ref_83
  article-title: Aurora Kinases as Anticancer Drug Targets
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-2179
  contributor:
    fullname: Gautschi
– volume: 7
  start-page: 31014
  year: 2016
  ident: ref_50
  article-title: Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8826
  contributor:
    fullname: Fiorentino
– volume: 11
  start-page: 3590
  year: 2020
  ident: ref_118
  article-title: NRXN1 as a Novel Potential Target of Antibody-Drug Conjugates for Small Cell Lung Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27718
  contributor:
    fullname: Yotsumoto
– volume: 13
  start-page: 1309
  year: 2021
  ident: ref_145
  article-title: Combination of Bevacizumab and Dual Immunotherapy for Extensive-Disease Small-Cell Lung Cancer: A Case Report
  publication-title: Immunotherapy
  doi: 10.2217/imt-2021-0025
  contributor:
    fullname: Song
– volume: 12
  start-page: 4864
  year: 2023
  ident: ref_80
  article-title: Immunogenicity of Small-cell Lung Cancer Associates with STING Pathway Activation and Is Enhanced by ATR and TOP1 Inhibition
  publication-title: Cancer Med.
  doi: 10.1002/cam4.5109
  contributor:
    fullname: Li
– volume: 16
  start-page: 1259
  year: 2016
  ident: ref_27
  article-title: ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2016.06.081
  contributor:
    fullname: Borromeo
– volume: 8
  start-page: 28725
  year: 2017
  ident: ref_82
  article-title: Association of Tumor TROP2 Expression with Prognosis Varies among Lung Cancer Subtypes
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15647
  contributor:
    fullname: Inamura
– volume: 22
  start-page: 51
  year: 2021
  ident: ref_11
  article-title: Durvalumab, with or without Tremelimumab, plus Platinum–Etoposide versus Platinum–Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-Label, Phase 3 Trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30539-8
  contributor:
    fullname: Goldman
– volume: 7
  start-page: 32164
  year: 2022
  ident: ref_100
  article-title: KC-180-2 Exerts Anti-SCLC Effects via Dual Inhibition of Tubulin Polymerization and Src Signaling
  publication-title: ACS Omega
  doi: 10.1021/acsomega.2c03408
  contributor:
    fullname: Peng
– volume: 145
  start-page: 1036
  year: 1994
  ident: ref_109
  article-title: Small Cell Carcinomas of the Lung Express the Bcl-2 Protein
  publication-title: Am. J. Pathol.
  contributor:
    fullname: Kornstein
– volume: 11
  start-page: 74
  year: 2023
  ident: ref_65
  article-title: Combination Lurbinectedin and Doxorubicin versus Physician’s Choice of Chemotherapy in Patients with Relapsed Small-Cell Lung Cancer (ATLANTIS): A Multicentre, Randomised, Open-Label, Phase 3 Trial
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(22)00309-5
  contributor:
    fullname: Aix
– volume: 14
  start-page: 1032
  year: 2019
  ident: ref_90
  article-title: Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.01.028
  contributor:
    fullname: Hsu
– volume: 108
  start-page: 1378
  year: 2017
  ident: ref_131
  article-title: Impact of MET Inhibition on Small-cell Lung Cancer Cells Showing Aberrant Activation of the Hepatocyte Growth Factor/ MET Pathway
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13268
  contributor:
    fullname: Taniguchi
– volume: 24
  start-page: 5143
  year: 2018
  ident: ref_78
  article-title: Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0401
  contributor:
    fullname: Laird
– volume: 70
  start-page: 4009
  year: 2013
  ident: ref_89
  article-title: Checkpoint Kinase 1 in DNA Damage Response and Cell Cycle Regulation
  publication-title: Cell. Mol. Life Sci.
  doi: 10.1007/s00018-013-1307-3
  contributor:
    fullname: Patil
– volume: 22
  start-page: 531
  year: 2021
  ident: ref_92
  article-title: A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2021.04.005
  contributor:
    fullname: Byers
– volume: 15
  start-page: 274
  year: 2020
  ident: ref_87
  article-title: Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.10.013
  contributor:
    fullname: Owonikoko
– volume: 2
  start-page: 798
  year: 2012
  ident: ref_70
  article-title: Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0112
  contributor:
    fullname: Byers
– volume: 24
  start-page: 1944
  year: 2018
  ident: ref_76
  article-title: Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-0443
  contributor:
    fullname: Tang
– volume: 15
  start-page: e17313
  year: 2023
  ident: ref_81
  article-title: ATR Inhibition Augments the Efficacy of Lurbinectedin in Small-cell Lung Cancer
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.202217313
  contributor:
    fullname: Schultz
– volume: 125
  start-page: 366
  year: 2021
  ident: ref_142
  article-title: Anlotinib vs Placebo as Third- or Further-Line Treatment for Patients with Small Cell Lung Cancer: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-021-01356-3
  contributor:
    fullname: Cheng
– volume: 524
  start-page: 47
  year: 2015
  ident: ref_12
  article-title: Comprehensive Genomic Profiles of Small Cell Lung Cancer
  publication-title: Nature
  doi: 10.1038/nature14664
  contributor:
    fullname: George
– volume: 16
  start-page: 299
  year: 2021
  ident: ref_144
  article-title: Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2020.10.002
  contributor:
    fullname: Fan
– volume: 3
  start-page: 1
  year: 2019
  ident: ref_23
  article-title: Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
  publication-title: JCO Precis. Oncol.
  doi: 10.1200/PO.18.00386
  contributor:
    fullname: Offin
– volume: 3
  start-page: 5
  year: 2018
  ident: ref_52
  article-title: Targeting Oncogenic Myc as a Strategy for Cancer Treatment
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-018-0008-7
  contributor:
    fullname: Chen
– volume: 179
  start-page: 403
  year: 2019
  ident: ref_39
  article-title: Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, P53, and Notch
  publication-title: Cell
  doi: 10.1016/j.cell.2019.09.010
  contributor:
    fullname: Ouadah
– volume: 36
  start-page: 1068
  year: 2023
  ident: ref_64
  article-title: Onionin A Inhibits Small-Cell Lung Cancer Proliferation through Suppressing STAT3 Activation Induced by Macrophages-Derived IL-6 and Cell–Cell Interaction with Tumor-Associated Macrophage
  publication-title: Human Cell
  doi: 10.1007/s13577-023-00895-6
  contributor:
    fullname: Mito
SSID ssj0023259
Score 2.440733
SecondaryResourceType review_article
Snippet Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 105
SubjectTerms Auranofin
Cancer
Cancer therapies
Chemotherapy
Clinical trials
clinical vulnerability
Development and progression
Growth factors
Health aspects
heterogeneity
Humans
Immune system
Immunotherapy
inhibitor molecules
Kinases
Lung cancer
Lung cancer, Small cell
Lung Neoplasms - drug therapy
Medical prognosis
Metabolism
Metastasis
Morphology
Mutation
Prognosis
Proteins
Review
small cell lung cancer
Small Cell Lung Carcinoma - therapy
targeted therapy
Technology
Tobacco
Transcription factors
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ba9swFH6MQqGXsW7d5rUbHnTsZGpZkiUds7SljNHLVuhNyPIzy2jdkqSH_fu9JzshZoddRiCHSAHre3n69JGn7wGcBiK1pmyxwNipQoXaFY3pXKEkO8sYFDGkaovr-upGfb3VtzutvrgmbLAHHoA7Uy40qG0r2MquQxdE3TX8aol8ght2X6E3YmqUWrJKbdIEsU9Ra1cPJe-SBP7Z4tf9inhfcGvICRklz_6_d-YdapqWTe7w0OULeD4eIPPZ8OCH8Az7l7A_tJT8_QqqWbqowBei8vMlF13kF1zSuMoXff79Ptzd5XOkt2-U5PmcQ748gpvLix_zq2Lsi1BEXcp1EVvbxLaUBDPJS9NWygSrYt1YU2m00bQddwGzIfJpCSUfjGyHAkttLckj-Rr2-oce30LuGsWyNCQPHRHRGQyl7qIIARV2MoNPG4D842B_4Uk2MJB-F8gMvjB62zlsWp0-oFD6MZT-X6HM4DNj7zm1COAYxhsC9KhsUuVnxjhiWl3WGZxMZlJKxOnwJnp-TMmVrxxRccX_5GbwcTvM3-Qysx4fntIcSXpVW5fBmyHY2yVJy83mDS3VTn4GkzVPR_rFz2TYTRKb9kVRvfsfKB3DAbe855KaqjyBvfXyCd_TwWjdfEg58AdMlglG
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIlLxbspBQUJxMlq_Ehsn6rt0qVCiAtU6s1ynAksarPt7vbAv2fGyS4bIaFIe4i9UjzjeSXj72PsXcCgVhcNcIit5jpUjtemdVwrQpYxIGJI3RZfq_ML_fmyvBxeuK2GtsqNT0yOullEekd-LB16Ukkf4k5ubjmxRtHX1YFC4z57IAgJj06Kzz5tCy4lE1mawBjEq9JVfeO7wjL_eP7reoXRXxBB5CgkJeT-f_3zToAaN0_uRKPZY7Y_pJH5pNf7E3YPuqfsYU8s-fsZk5N0XIGOReUfl9R6kZ9RY-Mqn3f5t-twdZVPAX--oKnnU1L88jm7mJ19n57zgR2Bx7JQax4bW8emUChsLDJNI7UJVseqtkaWYKNpWuICsyFSzgSK0iPbgoCitBaLJPWC7XWLDg5Y7mpNxWlISDoigjMQirKNIgTQ0KqMvd8IyN_0IBgeiwcSpN8VZMZOSXrbOQRdnW4slj_8YAleu1BDaRtB2IQtuCCqtqarwWwiOJmxDyR7TwaGAo5hOCeAj0pQVX5iUNGYlhVVxo5GM9Ew4nh4oz0_GObK_91GGXu7HaZ_UrNZB4u7NEdh1Vpal7GXvbK3S1KWKOcNLtWOtsFozeORbv4zwXZjoY3eUcjD_z_XK_aIKO2pZUYWR2xvvbyD15j4rOs3aXf_AVvg_3Q
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fi9QwEB7OE8EX8ffVO6WC4lO1bdImeRBZ1zsOUV904d5Cmk51j72udvfg7r93Ju0uW84HKfShSaEzmWTmaybzAbxy5NSqtMYEfSMT6UqTVKoxiRRcWUZh5l3ItvhWns7k57PibA82bKODAlf_hHbMJzXrFm-v_lx_oAn_nhEnQfZ38_OLFXnyjMkeb8HtXArJtv5VbvcTKGwItGn8wyPhBbpPgb_x9sg5hRr-N1fqHVc1TqPc8Usn9-HeEFDGk94CHsAetg_hTk8xef0I8kk4uMAHpOJPHSdhxMec4riK5238_cItFvEU6faFJn08ZRPoHsPs5PjH9DQZeBISX6RinfhaV75OBamd4Kaqc6mclr6stMoL1F7VDbOCaec5ekLBgZJuMMO00JrgkngC--2yxQOITSUZprpQUyfzaBS6tGh85hxKbEQErzcKsr_7chiWYAQr0u4qMoKPrL1tHy5iHR4su592mBNWGldhoeuMqxQ2aFxWNhVfNcUVzuQRvGHdWx58UrB3w4kB-lQuWmUnShnyvEVaRnA06klTxI-bN6NnNxZmc0OuOeed3Qhebpv5TU47a3F5GfoIwq-FNhE87Qd7K5LQTD6vSFQ9MoORzOOWdv4rFPAmyE3rZJY_-28BD-Eu89xzHk2eHsH-urvE5xQNrasXwdD_AipUBjw
  priority: 102
  providerName: Scholars Portal
Title Actionable Driver Events in Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/38203275
https://www.proquest.com/docview/2912820464
https://www.proquest.com/docview/2913448589/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC10778712
https://doaj.org/article/49abe58d12744fe9a16fbfbfbd224a92
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED5tQ0i8IH4TGFGQQDxlTWInth-70jIhNk3ApL5ZjuOMojad2u6B_547J6ka8YYi-SG2pfh8l7sv-XwH8MGgUyuTysXO1jzmplBxKWoVc0aZZYRLrfFsi6vi4oZ_nefzIyj6szCetG_LxVmzXJ01i1-eW3m3sqOeJza6vpwgZEE9S7PRMRwLxnqM3sEshhF9S3FnCOhHi9-rLfr5lEpBDpyPz9H_75v4wBUNaZIHfmf2BB53AWM0bh_sKRy55hk8bEtI_nkO2dgfTKADUNHnDZEsoilRGLfRool-rMxyGU0cNt_QqKMJbfHmBdzMpj8nF3FXByG2ecJ2sa1kaauEoVgRTooq48JIbotSiix30oqqpqpf0liKjhyjQEjWLnVJLiXCIfYSTpp1415DpEpOMNT4nDmpdUo4k-S1TY1x3NUsgI-9gPRdm-5CI0wgQepDQQZwTtLbj6Ek1f7GenOru63SXJnS5bJKKQth7ZRJi7qkq8K4wagsgE8ke02mhAK2pjsRgI9KSan0WAiFnjVPigBOByPRBOywu9893ZngVmcKXW9Gf24DeL_vpplEK2vc-t6PYYhPc6kCeNVu9n5JTFJxeYFLlQM1GKx52IP66hN09_r55v-nvoVHVNieiDNZcgonu829e4fhz64MUefnAls5-xLCg_Pp1fX30H9KCMkt5dhechl6m_gLr5ELaw
link.rule.ids 230,315,733,786,790,870,891,2115,2236,12083,12792,21416,24346,27955,27956,31752,31753,33406,33407,33777,33778,43343,43633,43838,53825,53827,74100,74390,74657
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFH-CTgguE58jY0CQQJysJbEd2yfUlU4FSoVgk3azHMeBoi0dbXfgv-e9JC2NkFCkHGJHip_9vpzn3w_gtUOnViRlYMFXggmXG1aoyjDBCVlGhdS7ptpilk_OxccLedFtuK26ssqNTWwMdbnwtEd-nBm0pBn9iHt3_YsRaxT9Xe0oNG7DHkFu6gHsnYxnX75uUy6eNXRpKXohlkuTt6XvHBP94_nPqxX6_5QoIntOqcHu_9dC77iofvnkjj86vQ_7XSAZD9uZfwC3Qv0Q7rTUkr8fQTZsDizQwaj4_ZKKL-IxlTau4nkdf7tyl5fxKOBtisoej2jql4_h_HR8Npqwjh-BeZnwNfOlLnyZcBQ3ppmqzIRyWvi80CqTQXtVVsQGpp2nqClwCpB0FdKQSK0xTeJPYFAv6vAUYlMISk9dg6WT-mBUcImsfOpcEKHiEbzZCMhetzAYFtMHEqTdFWQEJyS9bR8Cr24eLJbfbacLVhhXBKnLlNAJq2BcmlcFXSXGE85kEbwl2VtSMRSwd91JAfxUAquyQ6UMelyZ5BEc9Xqiavh-82b2bKeaK_t3IUXwattMb1K5WR0WN00fjnmr1CaCg3ayt0PimkjnFQ5V95ZBb8z9lnr-owHuxlQb7WOaHf7_u17C3cnZ56mdfph9egb3iOCeCmiy5AgG6-VNeI5h0Lp40a31P-Y-A9o
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFH-CIRAXxDeBAUECcYoa23Fsn1DpVgZMExJM2s1yHId12tLRdof997znpF0jJBQph9iR4pf3mfz8fgDvHQa1Kq9DFnxTZIUrTVapxmSFoM4yKjDvItriqDw4Lr6dyJMe_7TsYZVrnxgddT339I18xA16Uk4_4kZND4v4sTf9dPknIwYp-tPa02nchjuUZBONg55-2RRfgkfiNIbxKCulKTsQvMCJo9nZxRIzAUZkkYPwFLv4_-urt4LVEEi5FZmmD-FBn1Km404HHsGt0D6Gux3J5PUT4OO4dYG2SKV7C4JhpPsEclymszb9eeHOz9NJwNMhmn06ISVYPIXj6f6vyUHWMyVkXuZilflaV77OBQoeC05V80I5Xfiy0orLoL2qG-IF085T_hQEpUq6CSzkUmssmMQz2GnnbXgBqakKKlRd7KrDfDAquFw2njkXitCIBD6sBWQvu4YYFgsJEqTdFmQCn0l6mznUxjpemC9-294qbGFcFaSuGfUpbIJxrGwqOmrMLJzhCXwk2VsyNhSwd_2eAXxUaltlx0oZjL0yLxPYHcxEI_HD4fXbs72RLu2NSiXwbjNMdxLwrA3zqzhHYAUrtUngefeyN0sSmujnFS5VD9RgsObhSDs7jS28sehGT8n4y_8_11u4h0puD78efX8F94npnpA0PN-FndXiKrzGfGhVvYmK_he2WAag
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Actionable+Driver+Events+in+Small+Cell+Lung+Cancer&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Guti%C3%A9rrez%2C+Mirian&rft.au=Zamora%2C+Irene&rft.au=Freeman%2C+Michael+R&rft.au=Enc%C3%ADo%2C+Ignacio+J&rft.date=2023-12-20&rft.pub=MDPI+AG&rft.issn=1422-0067&rft.eissn=1422-0067&rft.volume=25&rft.issue=1&rft_id=info:doi/10.3390%2Fijms25010105&rft.externalDocID=A779212506
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon